Press releases
These press releases are intended for journalists and analysts/investors.
-
Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS)
Read more -
Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have welcomed news that Anoro Ellipta (umeclidinium/vilanterol) will be reimbursed
Read more -
Breo® Ellipta® (fluticasone furoate/vilanterol) to be PBS listed as reimbursed treatment for asthma and COPD
Affordable treatment options for Australian patients with asthma and chronic obstructive pulmonary disease (COPD) are set to expand
Read more -
GSK leads Access to Medicines Index 2014
The Access to Medicines Index published today has ranked GSK top for the fourth consecutive time
Read more -
GSK announces multi-million dollar investment in next generation manufacturing
GSK Australia has announced today it will be investing AUD$31 million in next generation manufacturing technology
Read more -
Indigenous and refugee programs win immunisation boost
Winners are from across Australia and include medical groups in Mildura, Townsville, Geraldton and Brisbane. They each receive $20,000
Read more -
GSK transitions to online versions of Consumer Medicine Information (CMI) leaflets for prescription only medicines
To ensure we provide the most up-to-date consumer medicine information (CMI) to patients, GSK will no longer be providing CMI leaflets
Read more -
Plant drugs and snail venom: Revolutionary drug research wins GSK award
Plants with peptide-based drugs in their seeds and leaves, and pain relief from cone snail venom are two of the innovative applications
Read more -
Pharmacy/Wholesaler level recall of two batches of Zovirax® Ophthalmic Ointment (aciclovir 3%)
Zovirax® Ophthalmic Ointment is used to treat herpes simplex virus infections of the cornea of the eye.
Read more -
Arzerra® (ofatumumab) registered in Australia for first-line use in chronic lymphocytic leukaemia (CLL)
GlaxoSmithKline announced today that the Therapeutic Goods Administration (TGA) has registered Arzerra® (ofatumumab)
Read more -
International collaboration to develop inhaled form of oxytocin to manage bleeding after childbirth
GSK, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation join forces to develop oxytocin
Read more -
Night time bathroom visits - a trigger for men to visit the doctor
Men aged over 50 are being encouraged to see their doctor if they visit the bathroom more than once during the night
Read more -
Kimbra launches campaign to urge effective asthma management
Asthma Awareness Week – Popular recording artist and asthma sufferer Kimbra is joining forces with asthma experts and peak respiratory
Read more -
Medicines Research Unit to Close
GSK today announced it will be closing the Medicines Research Unit at the Prince of Wales Hospital in Sydney
Read more -
GSK Open Innovation brings opportunities to Australian & NZ innovators
Australian and New Zealand health innovators encouraged to apply for partnership with GSK to turn their ideas into reality
Read more -
GSK Response to Publication of Paracetamol in Low Back Pain Study (PACE)
Panadol is approved by the TGA for the effective relief of backache
Read more -
New medicine for lupus now available in Australia
GSK is pleased to announce that BENLYSTA® (belimumab) is now available in Australia for use as an add-on therapy in adult patients
Read more -
Incruse® Ellipta® (umeclidinium) approved in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse® Ellipta® (umeclidinium)
Read more -
Anoro® Ellipta® approved in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have proudly announced that the Therapeutic Goods Administration
Read more -
GSK Recognises Top Poppy Growers
Leaders in Australian poppy production, GSK awarded its top poppy producers at an award dinner held in Launceston last week
Read more
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Careers
GSK is a place where talented people do amazing things. Where you are encouraged to be you and create a meaningful impact.
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products.
